I don’t agree with this. I think they list NGIO now, get value working and money for NGIO and GNBT so business can be starting up. Then when a vaccine gets approved, an already listed NGIO will move substantially up from there.
“ Consequently, I think Joe delays the listing as much as possible, in order to add to the initial 500 million, the value given by the vaccine (which, confirming positive concrete data, could be worth a few billion).
So I expect a listing no earlier than half a year, with full vaccine results ... ”
(6)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.